ConductScience.org, home

Paper33320447

Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.

Mveang Nzoghe A and 8 others. Immun Inflamm Dis, 2021. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2. Papers, record 33320447. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33320447

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.
PubMed
Journal
Immun Inflamm Dis
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
1.08
iCite
Revised in PubMed
2021-02-11
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mveang Nzoghe AAmandine
2Essone PNPaulin N
3Leboueny MMarielle
4Maloupazoa Siawaya ACAnicet Christel
5Bongho ECEliode Cyrien
6Mvoundza Ndjindji OOfilia
7Avome Houechenou RMRotimi Myrabelle
8Agnandji STSelidji Todagbe
9Djoba Siawaya JFJoel Fleuryhttps://orcid.org/0000-0002-0369-0153

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
COVID-19Major topic
Cross ReactionsMajor topic
Host-Pathogen InteractionsMajor topic
Immunity, HumoralMajor topic
SARS-CoV-2Major topic
Adult
Antibodies, Viral
Female
Humans
Immunologic Memory
Male
Middle Aged
Seroepidemiologic Studies

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
The Delegation of the European Union in Gabon, Sao Tome and Principe and ECCASPubMed
CHU-Mère-Enfant; Fondation Jeanne EBORIPubMed

Source PubMed

Download CSV of grants

References12

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123175507Pre-existing immunity against vaccine vectors--friend or foe?Microbiology (Reading)2013https://conductscience.org/library/papers/23175507PubMed
232747400Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2.J Clin Microbiol2020https://conductscience.org/library/papers/32747400PubMed
332814955Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer.Am J Clin Pathol2020https://conductscience.org/library/papers/32814955PubMed
429978039Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells.Sci Adv2018https://conductscience.org/library/papers/29978039PubMed
519745214Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.N Engl J Med2009https://conductscience.org/library/papers/19745214PubMed
631508246Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination.NPJ Vaccines2019https://conductscience.org/library/papers/31508246PubMed
733320447Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.Immun Inflamm Dis2021https://conductscience.org/library/papers/33320447PubMed
832213337Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.Lancet Infect Dis2020https://conductscience.org/library/papers/32213337PubMed
933397903Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray.Nat Commun2021https://conductscience.org/library/papers/33397903PubMed
1032808976Humoral Immune Response to SARS-CoV-2.Am J Clin Pathol2020https://conductscience.org/library/papers/32808976PubMed
1132636479Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.Nat Rev Immunol2020https://conductscience.org/library/papers/32636479PubMed
1231160610M. tuberculosis infection and antigen specific cytokine response in healthcare workers frequently exposed to tuberculosis.Sci Rep2019https://conductscience.org/library/papers/31160610PubMed

Download CSV of references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
39887249mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.J Virol2025https://conductscience.org/library/papers/39887249PubMed
39198763Neopterin production in relation to COVID-19 in the Haut-Ogooué Province, Gabon.BMC Infect Dis2024https://conductscience.org/library/papers/39198763PubMed
39164256Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39164256PubMed
38838076Time to SARS-CoV-2 clearance in African, Caucasian, and Asian ethnic groups.Influenza Other Respir Viruses2024https://conductscience.org/library/papers/38838076PubMed
37242383Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies.Pathogens2023https://conductscience.org/library/papers/37242383PubMed
37186902Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants.Libyan J Med2023https://conductscience.org/library/papers/37186902PubMed
36992136Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity.Vaccines (Basel)2023https://conductscience.org/library/papers/36992136PubMed
36756213The COVID-19 pandemic in sub-Saharan Africa: The significance of presumed immune sufficiency.Afr J Lab Med2023https://conductscience.org/library/papers/36756213PubMed
36247198Covid-19: Early Cases and Disease Spread.Ann Glob Health2022https://conductscience.org/library/papers/36247198PubMed
35902675Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic.Sci Rep2022https://conductscience.org/library/papers/35902675PubMed
35686525Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic.J Zhejiang Univ Sci B2022https://conductscience.org/library/papers/35686525PubMed
35373190The Pandemic Experience in Southeast Asia: Interface Between SARS-CoV-2, Malaria, and Dengue.Front Trop Dis2021https://conductscience.org/library/papers/35373190PubMed
34966142Why Does the Severity of COVID-19 Differ With Age?: Understanding the Mechanisms Underlying the Age Gradient in Outcome Following SARS-CoV-2 Infection.Pediatr Infect Dis J2022https://conductscience.org/library/papers/34966142PubMed
34615863SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.Nat Commun2021https://conductscience.org/library/papers/34615863PubMed
34519768Demographic and Clinical Characteristics Associated With Severity, Clinical Outcomes, and Mortality of COVID-19 Infection in Gabon.JAMA Netw Open2021https://conductscience.org/library/papers/34519768PubMed
34442823SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes.Microorganisms2021https://conductscience.org/library/papers/34442823PubMed
34442723Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study.Microorganisms2021https://conductscience.org/library/papers/34442723PubMed
34230895Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing.Transl Med Commun2021https://conductscience.org/library/papers/34230895PubMed
34162141An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.Int Immunopharmacol2021https://conductscience.org/library/papers/34162141PubMed
33853839Cross-Reactivity of Two SARS-CoV-2 Serological Assays in a Setting Where Malaria Is Endemic.J Clin Microbiol2021https://conductscience.org/library/papers/33853839PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33320447

GET https://conductscience.org/api/papers/v1/33320447/cited_by?page=2